09th week of 2014 patent applcation highlights part 46 |
Patent application number | Title | Published |
20140057810 | DRILLING FLUID CONTAINING A SURFACTANT HAVING A HIGH BOILING POINT AND A LONG CHAIN TAIL GROUP - According to an embodiment, an invert emulsion drilling fluid comprises: an external phase, wherein the external phase of the drilling fluid comprises a hydrocarbon liquid; an internal phase, wherein the internal phase of the drilling fluid comprises water; and a surfactant, wherein the surfactant: (A) comprises a hydrophobic tail group having a carbon chain length greater than or equal to 16; (B) has a boiling point greater than or equal to 400° F. (204.4° C.); and (C) is in at least a sufficient concentration such that the surfactant spontaneously forms reverse-micelles. According to another embodiment, a method of using the invert emulsion drilling fluid comprises: introducing the drilling fluid into a well. | 2014-02-27 |
20140057811 | CURABLE COMPOSITION FOR USE AS LOST CIRCULATION MATERIAL - The present invention relates to compositions and methods for reducing or preventing the loss of drilling fluids and other well servicing fluids into a subterranean formation during drilling or construction of boreholes in said formation. Specifically, this invention comprises a curable composition capable of free radical polymerization for creating lost circulation material in-situ. The curable composition comprises an organic compound capable of free radical (co)polymerization represented by the formula (I): wherein x is an integer from 1 to 8; Fp comprises one or more moiety comprising a free radical polymerizable group; L is an organic moiety comprising a (substituted) aromatic or (substituted) aliphatic group comprising one or more O, N, S, or combinations thereof; and Q comprises a substituted or unsubstituted mono- or polyvalent organic radical comprising one or one or more moiety selected from alkyl, alkylene, alkenyl, cycloalkyl, cycloalkylene, aryl, aralkyl, alkaryl, poly(oxyalkylene), poly(carboalkoxyalkylene), a substituted heterocyclic radical, or an unsubstituted heterocyclic radical. | 2014-02-27 |
20140057812 | Self-Assembling Materials for Wellbore Servicing and Methods of Using Same - A method of servicing a wellbore penetrating a formation comprising placing a wellbore servicing fluid comprising a modified proppant pack into the wellbore or formation wherein the modified proppant pack comprises a proppant and a self-assembly directing material. A modified proppant pack comprising a proppant and a self-assembly directing material comprising a water-soluble moiety, an oil-soluble moiety and a crosslinkable moiety. | 2014-02-27 |
20140057813 | HYDRAULIC FRACTURING WITH IMPROVED VISCOSITY LIQUEFIED INDUSTRIAL GAS BASED SOLUTION - The present invention is a cryogenic subterranean fracturing fluid, comprising a liquefied industrial gas and a viscosity increasing additive. The liquefied industrial gas may be liquefied carbon dioxide, liquefied nitrogen, or a blend of the two. The liquefied industrial gas mixture should be substantially free of water. In this context, substantially free of water means less than 10% water by volume, or preferably less than 5% water by volume. In addition to the viscosity increasing additive, a proppant may be added to the fracturing fluid. In addition to the viscosity increasing additive and/or proppant additional additives may be added to the liquefied industrial gas as required. | 2014-02-27 |
20140057814 | GUM ARABIC ENCAPSULATION OF REACTIVE PARTICLES FOR ENHANCED DELIVERY DURING SUBSURFACE RESTORATION - The present invention relates to emulsion compositions comprising iron particles (e.g., nanoscale zero valent iron particles) and methods of use thereof for remediation of contaminated environmental sites (e.g., contaminated subsurface environments). | 2014-02-27 |
20140057815 | METHODS AND COMPOSITIONS FOR ENHANCING GUAR HYDRATION RATES AND PERFORMING GUAR DERIVATIZATION REACTIONS - Methods are provided that include, but are not limited to, methods of treating guar splits comprising: exposing guar splits to a treatment chemical to create treated guar splits, wherein the treatment chemical comprises at least one treatment chemical selected from the group consisting of: an aqueous salt solution; a caustic solution, and a derivatizing agent; and grinding the treated guar splits to create ground, treated guar splits. | 2014-02-27 |
20140057816 | LOW INTERFACIAL TENSION SURFACTANTS FOR PETROLEUM APPLICATIONS - The invention relates to a class of novel surfactants that have utility in the recovery and/or extraction of oil. | 2014-02-27 |
20140057817 | METHOD OF SCAVENGING HYDROGEN SULFIDE AND/OR SULFHYDRYL COMPOUNDS - A method of reducing the amount of sulfhydryl compounds from sour hydrocarbon fluids is described. In the method, an aldehyde-releasing compound, which is high temperature stable and is highly water-soluble, is introduced to a hydrocarbon fluid stream as a scavenger for sulfhydryl compounds. The aldehyde-releasing compound is allowed to mix with the hydrocarbon fluid stream and the aldehyde-releasing compound is allowed to react with the sulfhydryl compounds present in the hydrocarbon fluid stream, thereby reducing the presence sulfhydryl compound in the hydrocarbon fluid stream. | 2014-02-27 |
20140057818 | Lubricating Composition Containing an Antiwear Agent - The invention provides a lubricating composition containing an antiwear agent and an oil of lubricating viscosity. The invention further relates to the use of the lubricating composition in an internal combustion engine, or a driveline device. | 2014-02-27 |
20140057819 | USE OF BLOCK-COPOLYMERIC POLYALKYLENE OXIDES AS FRICTION REDUCERS IN SYNTHETIC LUBRICANTS - The invention relates to the use of block copolymers containing at least a block of aromatic oxyalkylene groups and a block of nonaromatic oxyalkylene groups as friction-reducing additive and also compositions and lubricant formulations containing the block copolymers of the invention. | 2014-02-27 |
20140057820 | COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Chemical compositions and method of making the same are disclosed. The disclosed chemical compositions are particularly useful in methods of removing unwanted components within a papermaking process. | 2014-02-27 |
20140057821 | Dyed Coated Bleach Materials - The invention relates to dyed particles of a bleach material that comprise a coating. The invention also relates to the use of the dyed particles in detergent compositions. | 2014-02-27 |
20140057822 | Container - Packaged detergent composition comprising a container that at least partly disintegrates in an aqueous environment, the detergent composition comprising at least one liquid and at least one solid substantially insoluble in the liquid and preferably having a size sufficient to be retained by a 2.5 mm mesh wherein the at least one solid has a density lower than the density of the liquid | 2014-02-27 |
20140057823 | Carpet Cleaning Composition - A carpet cleaning detergent comprises:
| 2014-02-27 |
20140057824 | Liquid Soaps with Triclocarban - An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount Othat is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition. | 2014-02-27 |
20140057825 | FUNCTIONALIZED SUBSTRATES COMPRISING PERFUME MICROCAPSULES - A functionalized substrate. | 2014-02-27 |
20140057826 | COMPOSITIONS OF HYDROCHLOROFLUOROOLEFINS - The present invention relates to solvent/cleaner and heat transfer fluid compositions comprising at least one hydrochlorofluoroolefin (HCFO), 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd), particularly the trans-isomer. The HCFO of the present invention can be used in combination with co-agents including, hydrofluorocarbons (HFCs), hydrofluomolefins (HFOs), hydrocarbons, ethers including hydrofluoroethers (HFEs), esters, ketones, alcohols, 1,2-transdichloroethylene and mixtures thereof. | 2014-02-27 |
20140057827 | FABRIC CONDITIONERS - An aqueous fabric conditioner composition comprising (a) from 2 to 9 wt % of a fabric softening active, by weight of the total composition, wherein the fabric softening active is an ester-linked quaternary ammonium compound having fatty acid chains comprising from 20 to 35 wt % of saturated C18 chains and from 20 to 35 wt % of monounsaturated C18 chains, by weight of total fatty acid chains; and (b) from 0.01 to 0.5 wt %, by weight of the total composition, of a floc prevention agent, which is a non-ionic alkoxylated material having an HLB value of from 8 to 18, wherein the aqueous fabric conditioner composition has a viscosity of greater than 50 cps, preferably from 55 to 200 cps as measured on a cup and bob viscometer; the viscosity being continuously measured under shear at 106 s″1 for 60 seconds, at 25° C. and wherein the composition leads to little or no floc formation upon addition to water. | 2014-02-27 |
20140057828 | Small Peptide Modulators of Potassium Channel Trafficking - Provided herein are methods of improving electrolyte balance across a cell membrane and treating pathophysiological conditions associated with electrolyte imbalance. Improvement or treatment is effected by ontacting the cell or administering a peptide modulator that increases the surface expression of Ca | 2014-02-27 |
20140057829 | Citrullinated Histone H3 (Cit H3) in Septic Shock - Methods of diagnosing sepsis, severe sepsis, or septic shock and predicting prognosis in subjects with septic shock, based on levels of citrullinated histone H3 (Cit H3) in the subject, e.g., in a sample comprising serum (e.g., whole blood, serum, or plasma), cerebrospinal fluid, urine, saliva, or peritoneal fluid from the subject. | 2014-02-27 |
20140057830 | ALPHABODIES SPECIFICALLY BINDING TO CYTOKINES OR GROWTH FACTORS AND/OR CYTOKINE OR GROWTH FACTOR RECEPTORS - Alphabodies that specifically bind to cytokines or growth factor and/or their receptors, as well as polypeptides that comprise or essentially consist of such Alphabodies. Further nucleic acids encoding such Alphabodies; methods for preparing such Alphabodies and polypeptides; host cells expressing or capable of expressing such Alphabodies and polypeptides; compositions, and in particular pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells; and uses of such Alphabodies or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2014-02-27 |
20140057831 | ANTI-FIBROTIC PEPTIDES AND THEIR USE IN METHODS FOR TREATING DISEASES AND DISORDERS CHARACTERIZED BY FIBROSIS - The invention provides methods and compositions for inhibiting and/or reversing fibrosis. The invention further provides peptides and polypeptides which are BMP agonists which trigger BMP signaling and inhibit and/or reverse EMT in a cell or tissue. | 2014-02-27 |
20140057832 | USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE - The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness. | 2014-02-27 |
20140057833 | ADIPONECTIN RECEPTOR AGONISTS AND METHODS OF USE - Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided. | 2014-02-27 |
20140057834 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. | 2014-02-27 |
20140057835 | METHODS FOR TREATING HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2014-02-27 |
20140057836 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds. | 2014-02-27 |
20140057837 | METHODS AND COMPOSITIONS FOR THE "BROWNING" OF WHITE FAT - Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become brown adipose tissue in a subject include the administration of one or more agents. The agent can increase or induce hypothalamic expression of BDNF, can be a TrkB receptor agonist or a beta-3 adrenergic receptor agonist, or encode an agonist that modulates a hypothalamic-adipocyte axis. | 2014-02-27 |
20140057838 | OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM - Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and play a role in glucose metabolism. The present invention relates to methods for treating or preventing diseases such as diabetes, metabolic syndrome, and obesity or obesity-related by administering a therapeutically effective amount of osteoblast-expressed Lcn-2 or a biologically active fragment. | 2014-02-27 |
20140057839 | FORMULATIONS AND METHODS FOR WEIGHT LOSS AND BODY CONTOURING - Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually. | 2014-02-27 |
20140057840 | ANTI-ANDROGENIC AGENT, SEBUM SECRETION BLOCKER, HAIR GROWTH STIMULANT, AND FOOD OR BEVERAGE - Provision of an anti-androgenic agent which has a strong anti-androgenic action, is free of side effects and very safe, and a sebum secretion blocker and a hair growth stimulant containing the anti-androgenic agent as an active ingredient. Provided are the anti-androgenic agent comprising lactoferrin, the sebum secretion blocker containing the anti-androgenic agent as an active ingredient, the hair growth stimulant containing the anti-androgenic agent as an active ingredient, and a food or drink product comprising the anti-androgenic agent containing lactoferrin as an active ingredient. | 2014-02-27 |
20140057841 | HUMAN INSULIN AND ANALOG CONJUGATE THEREOF - Disclosed is a recombinant human insulin or analog conjugate thereof. Said conjugate is formed by connecting the ε-amino group of lysine 29 of the B chain to activated polyethylene glycol by means of an amide bond. Further disclosed is a method of preparing said conjugate, a pharmaceutical compound, and a use for said conjugate in preparing medication for treating Type 1 and Type 2 diabetes. | 2014-02-27 |
20140057842 | COMPOSITIONS AND METHODS FOR CELL HOMING AND ADIPOGENESIS - Provided is a method of causing a cell to migrate to a scaffold and there differentiate to form adipose or adipose-like cells or tissue. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising a cell homing composition and an adipogenic composition. Additionally, a method of making a tissue scaffold capable of recruiting a cell and differentiating the recruited cell to form adipose or adipose-like cells or tissue is provided. | 2014-02-27 |
20140057843 | COMPOSITIONS FOR DIETARY HEALTH MANAGEMENT - This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of any one of the disease states in the group consisting of cardiovascular disease, inflammation and diarrhoea. Human evolution has been a very slow process in contrast to the relatively recent, rapid changes in our diet since the Neolithic revolution which marked the switch from hunter-gatherer to agricultural life-style around 10,000 years ago. Moreover our genome has not had time to evolve at the same pace and therefore it is postulated that our bodies will work more efficiently with an ancestral diet. In a first aspect of the invention, a plurality of compositions for the dietary health management system of a human being is provided, wherein the plurality of compositions comprise a daily diet of: (g) 1750 to 2750 kilocalories (7350 to 11550 kiloJoules); (h) have more than 1250, preferably more than 1450, more preferably more than 1650 mg gallic acid equivalents of polyphenols; (i) have more than 40, preferably more than 50, more preferably more than 60 g fibre; (j) have more than 130, preferably more than 150, more preferably more than 170 g protein (k) have 0 to 2, preferably 0 to 1.5, most preferably 0 to 1 g starch; and (I) have 0 to 5, preferably 0 to 2.5, most preferably 0 to 1 g lactose. | 2014-02-27 |
20140057844 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies. | 2014-02-27 |
20140057845 | COMPOSITION FOR TREATING, IMPROVING, OR PREVENTING PAIN - In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats. | 2014-02-27 |
20140057846 | PRODUCTS AND METHODS USING SOY PEPTIDES TO LOWER TOTAL AND LDL CHOLESTEROL LEVELS - Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made. | 2014-02-27 |
20140057847 | CARDIOPROTECTIVE EFFECTS OF GHRH AGONISTS - Disclosed herein are methods demonstrating that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 μg/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function. Whereas, both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased anti-apoptotic gene expression. Collectively, these findings demonstrate that within the heart, GHRH-agonists can activate cardiac repair following MI. | 2014-02-27 |
20140057848 | FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE - The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake. | 2014-02-27 |
20140057849 | WILD-TYPE APOLIPOPROTEIN L-I FOR USE IN THE PREVENTION OF KIDNEY DISEASES - A wild-type human Apolipoprotein L-I is used in a method for the prevention and/or the treatment of renal disease. | 2014-02-27 |
20140057850 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS - The present invention relates to a peptide of the following formula (I) X | 2014-02-27 |
20140057851 | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma - Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.01). | 2014-02-27 |
20140057852 | Treatment of Cancers with A-8R Peptide - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 2014-02-27 |
20140057853 | Treatment of Cancers with A-8R Peptide - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 2014-02-27 |
20140057854 | TOPICAL FORMULATIONS AND USES THEREOF - Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions. | 2014-02-27 |
20140057855 | CYCLOSPORIN COMPOSITIONS - A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein. | 2014-02-27 |
20140057856 | Compositions and Methods For Enhancing Sialic Acid Levels In Tissue - The invention relates to compositions and methods for increasing sialic acid uptake and/or incorporation into tissue following gastrointestinal ingestion of compositions that contain sialic acid. | 2014-02-27 |
20140057857 | Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof - Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene aryl cross-linking moieties. Compositions comprising the cross-linked proteins and peptides can be used as pharmaceutical delivery formulations. The cross-linked proteins and peptides can have improved properties, such as cell permeability, as compared to the parent protein or peptide. | 2014-02-27 |
20140057858 | METHOD FOR INCREASING EMBRYO IMPLANTATION RATE IN MOTHER'S UTERUS IN MAMMALS, USE OF AN EFFECTIVE AMOUNT OF BETA-GALACTOSIDE-BINDING LECTIN OR DERIVATIVES THEREOF, BETA-GALACTOSIDE-BINDING LECTIN OR DERIVATIVES AND PRODUCT - The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin. | 2014-02-27 |
20140057859 | Hyaluronate Compositions - The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same. | 2014-02-27 |
20140057860 | PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES AND METHOD OF MANUFACTURING THE SAME - The present invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and the method of preparation thereof. The aforesaid pharmaceutical composition is prepared by the following components in weight percent: 0.1%-0.3% scutellarin, 20%-25% co-surfactant, 40-50% surfactant, and 25-30% oil. The method of preparing the aforesaid pharmaceutical composition comprises the steps of: (1) dispersing scutellarin in co-surfactant and surfactant to obtain a mixture; (2) dispersing the mixture from step (1) in oil, and thermostatically and magnetically stirring the dispersion mixture under the temperature of 25° C. to 37° C., such that the components thereof are completely dissolved to obtain the pharmaceutical composition. Through the use of the selected pharmaceutical adjuvants having the ability to inhibit MRP2, the aforesaid pharmaceutical composition effectively improves absorption and bioavailability of scutellarin. The preparation of the aforesaid pharmaceutical composition is simple and convenient, and the pharmaceutical composition can be processed into a variety of dosage forms for oral administration. | 2014-02-27 |
20140057861 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLINE INDUCED CARDIOTOXICITY - The invention features methods and compositions feature lapatinib and/or rapamycin for treating or preventing a cardiac condition induced by anthracycline treatment. | 2014-02-27 |
20140057862 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF - Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | 2014-02-27 |
20140057863 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION - The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. | 2014-02-27 |
20140057864 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A RETROVIRUS INFECTION - The invention provides methods, compositions, and kits featuring a ribonucleoside chain terminator for use in preventing or inhibiting a retrovirus infection. | 2014-02-27 |
20140057865 | ANALYSIS OF NODES IN CELLULAR PATHWAYS - An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications. | 2014-02-27 |
20140057866 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER - Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase. | 2014-02-27 |
20140057867 | Compositions and Methods of Aloe Polysaccharides - The present invention describes a method for preparing a polymannan extract from freeze-dried | 2014-02-27 |
20140057868 | CATALYTIC HYDROGENOLYSIS OF A COMPOSITION OF A MIXTURE OF OLIGOSACCHARIDE PRECURSORS AND USES THEREOF - A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the manufacture of human milk oligosaccharides is also disclosed. | 2014-02-27 |
20140057869 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use - Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide. | 2014-02-27 |
20140057870 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-02-27 |
20140057871 | CYCLIC AMIDE DERIVATIVE | 2014-02-27 |
20140057872 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2014-02-27 |
20140057873 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE - There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid derivative thereof and a nitric oxide releasing group as depicted in the following structures: | 2014-02-27 |
20140057874 | OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE - Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula IV: | 2014-02-27 |
20140057875 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 2014-02-27 |
20140057876 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-02-27 |
20140057877 | Therapeutic polyamine compositions and their synthesis - This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be utilized to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure. | 2014-02-27 |
20140057878 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-02-27 |
20140057879 | CO-CRYSTALS OF TRAMADOL AND COXIBS - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. | 2014-02-27 |
20140057880 | ANTCIN DERIVATIVES IN COMBINATION WITH ANTI-CANCER DRUGS IN THE TREATMENT AND/OR PREVENTION OF TUMORS - The invention surprisingly found that antcin or an ester derivative, salt or a composition thereof in combination with an anti-tumor drug provides unexpected efficacy in inhibiting tumors, while retaining normal cells at high viability. In addition, the amount of the anti-tumor drug in chemotherapy can be reduced by combinatorially using antcin or an ester derivative, salt or a composition thereof in view of the fact that they play a role in adjuvant therapy. | 2014-02-27 |
20140057881 | Composition for the Treatment of Skin Conditions - A topical composition for the treatment of skin conditions. The composition comprises an antifungal agent, an anti-inflammatory agent and an antimicrobial agent together with a pharmaceutically acceptable excipient. The anti-inflammatory is present at a concentration of less than 0.01% wt of the composition and the antimicrobial agent has the general formula (I): (Formula (I)). | 2014-02-27 |
20140057882 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and the treatment of certain conditions such as COPD. | 2014-02-27 |
20140057883 | TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 2014-02-27 |
20140057884 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER COMPRISING STIGMASTEROL AND 5 BETA-HYDROXYSITOSTANOL ISOLATED FROM NAVICULA INCERTA - A novel use of phytosterol isolated from | 2014-02-27 |
20140057885 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS - Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid. | 2014-02-27 |
20140057886 | Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions - The present invention relates to compounds of formula (I): | 2014-02-27 |
20140057887 | NOVEL PLATINUM-CARBENE COMPLEXES AND USE THEREOF AS MEDICAMENTS - Disclosed are novel platinum-carbene complexes and use thereof as medicinal products. | 2014-02-27 |
20140057888 | COMPOUNDS AND THEIR USE - Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as β-lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of β-lactamases. These compounds restore/potentiate the activities of β-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting β-lactamases. | 2014-02-27 |
20140057889 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 2014-02-27 |
20140057890 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 2014-02-27 |
20140057891 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds - The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2014-02-27 |
20140057892 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE - The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD) heart failure, ischemia, and anemia. | 2014-02-27 |
20140057893 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT - Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included | 2014-02-27 |
20140057894 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS - Disclosed herein is a compound of Formula I: wherein X, R | 2014-02-27 |
20140057895 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF - The present invention relates to a novel indazole- or pyrrolopyridine-derivative comprising a 5 membered heterocyclic substituent at 1 position thereof which has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. | 2014-02-27 |
20140057896 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE - Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2014-02-27 |
20140057897 | METHOD OF TREATING MIXED LINEAGE LEUKEMIA GENE-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIAS - The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL. | 2014-02-27 |
20140057898 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2014-02-27 |
20140057899 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF - The present invention provides a new compound that has an inhibitory action against EGFR and that has cell growth inhibitory effects. The present invention further provides a pharmaceutical preparation useful for preventing and/or treating cancer, based on the EGFR inhibitory effect of the compound. A compound represented by the following Formula (I) | 2014-02-27 |
20140057900 | Pro-Neurogenic Compounds - Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. | 2014-02-27 |
20140057901 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to substituted xanthines of general formula | 2014-02-27 |
20140057902 | Diazepinone derivatives - The invention relates to compound of the formula I | 2014-02-27 |
20140057903 | METHODS FOR CHARACTERIZING AND TREATING COGNITIVE IMPAIRMENT IN AGING AND DISEASE - This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging. | 2014-02-27 |
20140057904 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 2014-02-27 |
20140057905 | CANCER DIAGNOSTICS, THERAPEUTICS, AND DRUG DISCOVERY ASSOCIATED WITH MACROPINOCYTOSIS - The present invention is directed to methods of inhibiting both proliferation and survival of cancer cells and for treating a subject having cancer. The present invention is further directed to methods of diagnosing cancer in a subject and identifying cancer therapeutics. | 2014-02-27 |
20140057906 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2014-02-27 |
20140057907 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2014-02-27 |
20140057908 | Method of Treating Cancer - This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF. | 2014-02-27 |
20140057909 | Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient - The present invention relates to an indole derivative, The indole derivative according to the present invention effectively inhibits the activity of diacylglycerol acyltransferase (DGAT) which induces metabolic diseases, such as obesity, diabetes, hyperlipidemia, or fatty liver and the like in lipid metabolism, thereby effectively regulating lipid metabolism and energy metabolism, and thus can be useful in pharmaceutical compositions for preventing or treating metabolic disease. | 2014-02-27 |